VANCOUVER, June 28 /PRNewswire-FirstCall/ - GeneMax Corp. , a biotechnology company specializing in the development of preventative vaccines and immunotherapeutics for cancer and infectious diseases announced today that it has received its lead vaccine candidate, AdhTAP(OS-1) from its PER.C6(R) technology licensor and contract manufacturer, Crucell (Leiden, The Netherlands). The proprietary adenovirus construct has been optimized to allow enhanced expression of the Transporter of Antigen Processing (TAP) that, in animal models, has been shown to increase both the killing of tumours by the immune system and animal survival.
"Receipt of the AdhTAP(OS-1) viral construct is an exciting and important milestone for GeneMax as it positions us to move forward with pre-clinical development of our leading oncology product," said Konstantine Sarafis, President and CEO of GeneMax. "The design, production and quality control of AdhTAP(OS-1) took two years to complete. GeneMax scientists have worked diligently to achieve this milestone and will now rapidly move to conclude testing of the vaccine enhancer in animal models of cancer, ready for manufacturing scale up and preclinical testing in humans. This is a notable accomplishment for GeneMax."
Larger scale production of AdhTAP(OS-1) will be performed using the PER.C6(R) cell line, licensed to GeneMax by Crucell. This proprietary cell line has been shown to be suitable for growth of the virus. Before filing an Investigational New Drug (IND) submission with the U.S. Food and Drug Administration (FDA), the company will complete toxicology studies and a third oncology model assessing the efficacy of AdhTAP(OS-1).
About AdhTAP(OS-1) Vaccine
TAPs (Transporters Associated with Antigen Processing) are proteins that are required for processing abnormal molecules that are expressed on the surface of cancer cells. These molecules are required for killing of tumours by the cell-mediated immune system. In many of the most widespread and lethal cancers, the TAP pathway is disrupted or turned off, making the tumours invisible to immune recognition. GeneMax has developed and patented technology to increase the expression of human TAPs. To produce the AdhTAP(OS-1) vaccine enhancer, the human TAP gene was cloned into a non-replicating adenovirus that is non-pathogenic to humans. The AdhTAP(OS-1) virus vector is used to deliver the human TAP gene to cells that initiate immune responses to cancer cells, resulting in enhanced immune responses against the tumour cells which now efficiently express the TAP protein on their surface. The power of the AdhTAP(OS-1) is that its use is not restricted to a single tumour type. Unlike most other anti-cancer vaccines, prior knowledge of the target molecules on the tumours is not required, making AdhTAP(OS-1) suitable for a wider variety of human cancers.
About GeneMax Corp.
GeneMax Corp. is an innovative biotechnology company specializing in the development of prophylactic vaccines and immunotherapeutics for the treatment and eradication of cancer and infectious diseases, using TAP (Transporters Associated with Antigen Presentation) to restore and augment antigen presentation and subsequent recognition and killing of target cells by the immune system.
SAFE HARBOR STATEMENT
THIS NEWS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS PRESS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR GENEMAX CORP. INCLUDE BUT ARE NOT LIMITED THE RISKS ASSOCIATED WITH PRODUCT DISCOVERY AND DEVELOPMENT AS WELL AS THE RISKS SHOWN IN GENEMAX'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING GENEMAX. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH OBTAINING GOVERNMENT GRANTS, THE SUCCESS OF PRECLINICAL AND CLINICAL TRIALS, THE PROGRESS OF RESEARCH AND PRODUCT DEVELOPMENT PROGRAMS, THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS, FUTURE CAPITAL REQUIREMENTS, AND GENEMAX'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH ACTIVITIES. THERE CAN BE NO ASSURANCE THAT GENEMAX'S DEVELOPMENT EFFORTS WILL SUCCEED, THAT SUCH PRODUCTS WILL RECEIVE REQUIRED REGULATORY CLEARANCE, OR THAT EVEN IF SUCH REGULATORY CLEARANCE WERE RECEIVED, THAT SUCH PRODUCTS WOULD ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. GENEMAX DISCLAIMS ANY INTENT OR OBLIGATIONS TO UPDATE THESE FORWARD-LOOKING STATEMENTS."